ID25824A - Formulasi terapeutik untuk memberikan tolterodin dengan pelepasan yang terkendali - Google Patents

Formulasi terapeutik untuk memberikan tolterodin dengan pelepasan yang terkendali

Info

Publication number
ID25824A
ID25824A IDP20001006A ID20001006A ID25824A ID 25824 A ID25824 A ID 25824A ID P20001006 A IDP20001006 A ID P20001006A ID 20001006 A ID20001006 A ID 20001006A ID 25824 A ID25824 A ID 25824A
Authority
ID
Indonesia
Prior art keywords
tolterodins
provide controlled
therapeutic formulation
therapeutic
formulation
Prior art date
Application number
IDP20001006A
Other languages
English (en)
Inventor
Lisbeth Nilvebrant
Bengt Hallen
Birgitta Olsson
Jan Strombom
Bo Kreilgard
L Orup Jacobsen
Ulla Hoeck
Helle Kristensen
Torkel Gren
Anders Ringberg
Martin Wikberg
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26663376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID25824(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9802864A external-priority patent/SE9802864D0/xx
Priority claimed from SE9803871A external-priority patent/SE9803871D0/xx
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Publication of ID25824A publication Critical patent/ID25824A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
IDP20001006A 1998-08-27 1999-08-26 Formulasi terapeutik untuk memberikan tolterodin dengan pelepasan yang terkendali ID25824A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9802864A SE9802864D0 (sv) 1998-08-27 1998-08-27 Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
SE9803871A SE9803871D0 (sv) 1998-11-11 1998-11-11 Therapeutic method and formulation

Publications (1)

Publication Number Publication Date
ID25824A true ID25824A (id) 2000-11-09

Family

ID=26663376

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP20001006A ID25824A (id) 1998-08-27 1999-08-26 Formulasi terapeutik untuk memberikan tolterodin dengan pelepasan yang terkendali

Country Status (30)

Country Link
US (1) US6770295B1 (id)
EP (2) EP1039882B1 (id)
CN (1) CN1239152C (id)
AP (1) AP1529A (id)
AR (1) AR029311A1 (id)
AT (1) ATE487471T1 (id)
AU (1) AU745190B2 (id)
BG (1) BG65168B1 (id)
CA (1) CA2311755C (id)
CY (1) CY1111088T1 (id)
CZ (1) CZ302630B6 (id)
DE (1) DE69942928D1 (id)
DK (1) DK1039882T3 (id)
EA (1) EA002720B1 (id)
GE (1) GEP20043354B (id)
HU (1) HUP0100437A3 (id)
ID (1) ID25824A (id)
IL (1) IL136294A (id)
IS (1) IS2976B (id)
ME (1) ME00850B (id)
MY (1) MY127946A (id)
NO (1) NO329830B1 (id)
NZ (1) NZ504618A (id)
OA (1) OA11636A (id)
PT (1) PT1039882E (id)
SI (1) SI1039882T1 (id)
SK (1) SK287111B6 (id)
TR (1) TR200001998T1 (id)
UA (1) UA72882C2 (id)
WO (1) WO2000012069A1 (id)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
DE19922662C1 (de) 1999-05-18 2000-12-28 Sanol Arznei Schwarz Gmbh Transdermales therapeutisches System (TTS) Tolterodin enthaltend
DE19932651A1 (de) * 1999-07-13 2001-01-18 Hexal Ag Transdermales therapeutisches System zur Anwendung von Tolterodin
HUP0203028A3 (en) * 1999-11-11 2005-07-28 Pharmacia Ab Pharmaceutical formulation containing tolterodine and its use
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US20030185882A1 (en) 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
EP1441707A1 (en) * 2001-11-09 2004-08-04 Pharmacia AB Anti-muscarinic agent and estrogen-agonist for treating unstable or overactive bladder
US6773421B2 (en) 2001-12-14 2004-08-10 Kimberly-Clark Worlwide, Inc. Combination for managing the involuntary loss of bladder control
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
AU2003303041B2 (en) * 2002-12-13 2008-07-24 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
MXPA05007767A (es) * 2003-01-22 2006-01-31 Pfizer Health Ab Dosis reducida de tolterodina y otros agentes antimuscarinicos para tratar trastornos urinarios.
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
EP1635795A1 (en) * 2003-05-30 2006-03-22 Ranbaxy Laboratories, Ltd. Controlled release pharmaceutical compositions of tolterodine and processes for their preparation
DE602004030931D1 (id) 2003-11-04 2011-02-17 Supernus Pharmaceuticals Inc
US8709476B2 (en) 2003-11-04 2014-04-29 Supernus Pharmaceuticals, Inc. Compositions of quaternary ammonium compounds containing bioavailability enhancers
WO2005105036A1 (en) * 2004-04-28 2005-11-10 Natco Pharma Limited Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation
EP1629834A1 (en) * 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
RU2301086C2 (ru) * 2004-12-27 2007-06-20 Государственное образовательное учреждение высшего профессионального образования Алтайский государственный медицинский университет Минздрава России (ГОУ ВПО АГМУ МЗ РФ) Способ лечения гиперактивного мочевого пузыря
ATE481096T1 (de) 2005-04-06 2010-10-15 Adamas Pharmaceuticals Inc Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
CN1330297C (zh) * 2005-07-04 2007-08-08 宛六一 酒石酸托特罗定软胶囊及其制备方法
KR20070012205A (ko) * 2005-07-22 2007-01-25 주식회사종근당 경시 안정성을 갖는 톨테로딘을 함유하는 제어방출형 펠렛
ES2593047T3 (es) 2006-02-03 2016-12-05 Opko Renal, Llc Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3
EP2015735A1 (en) * 2006-04-21 2009-01-21 Synthon B.V. Tolterodine beads
ES2670029T3 (es) 2006-06-21 2018-05-29 Opko Ireland Global Holdings, Ltd. Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D
HUE073014T2 (hu) 2007-04-25 2025-12-28 Opko Renal Llc Eljárás a másodlagos hyperparathyreoidismus biztonságos és hatékony kezelésére és megelõzésére krónikus vesebetegség esetén
US11752158B2 (en) 2007-04-25 2023-09-12 Eirgen Pharma Ltd. Method of treating vitamin D insufficiency and deficiency
KR20190028822A (ko) 2007-04-25 2019-03-19 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
CL2008001970A1 (es) * 2007-07-03 2009-03-27 Synthon Bv Perla con un nucleo de celulosa microcristalina, un recubrimiento soluble en agua con un polimero vinil pirrolidina, una capa con tolterodina y un aglutinante, y una capa de liberacion controlada con un poliacrilato; proceso para prepararla; forma de dosificacion, util en trastornos urinarios como vejiga hiperactiva.
US8486452B2 (en) * 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
EP2175843B1 (en) 2007-08-08 2014-10-08 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
US20090192228A1 (en) * 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
EP2281058B1 (en) 2008-04-02 2016-06-29 Opko Ireland Global Holdings, Ltd. Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders
TWI541246B (zh) 2008-12-08 2016-07-11 歐陸斯迪公司 二氫羥戊甲嗎啡
KR101004205B1 (ko) * 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
RU2396920C1 (ru) * 2008-12-29 2010-08-20 Николай Владимирович Карюкин Способ лечения гиперактивного мочевого пузыря
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
KR101746204B1 (ko) * 2010-02-18 2017-06-13 에스케이케미칼주식회사 피부 투과가 개선된 톨테로딘의 경피 투여용 조성물
WO2011123476A1 (en) 2010-03-29 2011-10-06 Cytochroma Inc. Methods and compositions for reducing parathyroid levels
WO2011137054A1 (en) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
WO2012017892A1 (ja) * 2010-08-03 2012-02-09 久光製薬株式会社 貼付剤及びその粘着力増強方法
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
JP7032322B2 (ja) 2016-03-28 2022-03-08 オプコ アイルランド グローバル ホールディングス リミテッド ビタミンｄ治療法
EP3808336A1 (de) * 2019-10-16 2021-04-21 ADD Advanced Drug Delivery Technologies, Ltd. Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
ZA933349B (en) * 1992-05-13 1994-06-15 Alza Corp Transdermal administration of oxybutynin
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
AU7994694A (en) * 1994-10-21 1996-05-15 Leiras Oy Controlled release oral delivery system containing oxybutynin
US5677346A (en) * 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
WO1998003067A1 (en) * 1996-07-19 1998-01-29 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
WO1998011888A1 (en) * 1996-09-19 1998-03-26 American Home Products Corporation Method of treating urinary incontinence

Also Published As

Publication number Publication date
CZ20001924A3 (cs) 2001-04-11
EP2153825A1 (en) 2010-02-17
SK7492000A3 (en) 2001-02-12
AP2000001823A0 (en) 2000-06-30
ME00850B (me) 2008-08-07
PT1039882E (pt) 2011-01-03
NO329830B1 (no) 2011-01-03
EP1039882B1 (en) 2010-11-10
CA2311755C (en) 2010-03-23
GEP20043354B (en) 2004-04-13
CN1287484A (zh) 2001-03-14
AR029311A1 (es) 2003-06-25
DE69942928D1 (de) 2010-12-23
NO20002977L (no) 2000-06-09
HUP0100437A3 (en) 2002-08-28
UA72882C2 (uk) 2005-05-16
IL136294A (en) 2004-02-08
MY127946A (en) 2007-01-31
DK1039882T3 (da) 2011-01-24
IL136294A0 (en) 2001-05-20
BG104476A (en) 2000-12-29
SI1039882T1 (sl) 2011-01-31
EP1039882A1 (en) 2000-10-04
EA002720B1 (ru) 2002-08-29
NO20002977D0 (no) 2000-06-09
TR200001998T1 (tr) 2001-01-22
CN1239152C (zh) 2006-02-01
AP1529A (en) 2006-01-03
IS2976B (is) 2017-07-15
ATE487471T1 (de) 2010-11-15
NZ504618A (en) 2002-09-27
US6770295B1 (en) 2004-08-03
EA200000468A1 (ru) 2000-12-25
CZ302630B6 (cs) 2011-08-10
IS5537A (is) 2000-06-15
SK287111B6 (sk) 2009-12-07
WO2000012069A1 (en) 2000-03-09
AU5891899A (en) 2000-03-21
OA11636A (en) 2004-09-03
HUP0100437A2 (hu) 2002-05-29
AU745190B2 (en) 2002-03-14
HK1034664A1 (en) 2001-11-02
CY1111088T1 (el) 2015-06-11
CA2311755A1 (en) 2000-03-09
BG65168B1 (bg) 2007-05-31

Similar Documents

Publication Publication Date Title
ID25824A (id) Formulasi terapeutik untuk memberikan tolterodin dengan pelepasan yang terkendali
EE04390B1 (et) Paikne preparaat dermatoloogiliste seisundite raviks
ID22878A (id) Komposisi aktif secara terapi
ID26334A (id) Morfolinol yang aktif secara farmasi
ID19875A (id) Poliolefin yang dimodifikasi menurut reologi
ID22939A (id) Formulasi-formulasi farmasi yang mengandung vorikonozal
ID21236A (id) Penggunaan komposisi bioaktif yang dikapsulkan
DK1637127T3 (da) Terapeutisk mikroskum
ID26330A (id) Polipeptida-polipeptida yang bergantung vitamin k yang dimodifikasi
IS2277B (is) Meðferðarlegar bíarýl afleiður
ID28962A (id) Komposisi poliolefin yang tahan benturan
ID20837A (id) Mikrokapsul dengan laju pelepasan yang mudah disesuaikan
NO20022692D0 (no) Terapeutiske midler
ID26317A (id) Formulasi pelepasan yang diperpanjang
IS6575A (is) Hýdroxýfenýl-píperidín-4-ýlíden-metýl-bensamíðafleiður til að meðhöndla sársauka
ID28441A (id) Terapi untuk memperbaiki kesadaran
ID24259A (id) Formulasi obat yang memiliki pelepasan senyawa aktif terkontrol
ID29966A (id) Sulfoniloksazolamina-sulfoniloksazolamina sebagai senyawa-senyawa aktif terapi
ID26474A (id) Komposisi kosmetik topikal yang mengandung benzaldoksim
ID29792A (id) Formulasi lepas terkendali untuk mengobati corp
IS6563A (is) Hýdroxýfenýl-píperasinýl-metýl-bensamíðafleiður til að meðhöndla sársauka
ID24617A (id) Komposisi kosmetik yang mengkondisikan kulit
IS6574A (is) Kínólinýl-píperidín-4-ýlíden-metýl-bensamíðafleiður til að meðhöndla sársauka
ID24060A (id) Pengolahan kulit hewan yang ditingkatkan
ID27096A (id) Komposisi farmasi yang baru